Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise
Executive Summary
Dermapharm has high hopes for 2023 as its acquisition of Arkopharma means the firm is now the number-one and number-three player respectively in the French and Spanish supplements markets.
You may also be interested in...
Dermapharm Expands Natural Offering With France's Arkopharma
Germany's Dermapharm will pay €450m to acquire herbal specialist Arkopharma to expand its footprint in Europe's consumer health market in countries such as France, Spain and Italy.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.